Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Cyclophosphamide 2043Radiotherapy 1859Cisplatin 1826Carboplatin 1533Gemcitabine 1435Paclitaxel 1291Bevacizumab 1271Docetaxel 1202pembrolizumab 1201Oxaliplatin 1160Capecitabine 1145Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 864Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 609fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × apraclonidine × Clear all
NCT05045248 2021-09-16

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

American University of Beirut Medical Center

Phase 2 Completed
10 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡